Management of chronic urticaria in Asia: 2010 AADV consensus guidelines
Asia Pacific Allergy
;
(4): 149-160, 2012.
Article
in English
| WPRIM
| ID: wpr-749894
ABSTRACT
This guideline is a result of a consensus reached during the 19th Asian-Australasian Regional Conference of Dermatology by the Asian Academy of Dermatology and Venereology Study Group in collaboration with the League of Asian Dermatological Societies in 2010. Urticaria has a profound impact on the quality of life in Asia and the need for effective treatment is required. In line with the EAACI/GA2LEN/EDF/WAO guideline for the management of urticaria the recommended first-line treatment is new generation, non-sedating H1-antihistamines. If standard dosing is ineffective, increasing the dosage up to four-fold is recommended. For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment. In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Asia
/
Quality of Life
/
Urticaria
/
Venereology
/
Cyclosporine
/
Cooperative Behavior
/
Consensus
/
Asian People
/
Dermatology
Type of study:
Practice guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Asia Pacific Allergy
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS